Bristol Myers Squibb Receives FDA Approval for ZENBEXUS in Multiple Myeloma Treatment
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
The U.S. FDA has granted accelerated approval to Bristol Myers Squibb's first CELMoD therapy, ZENBEXUS™, in combination with Daratumumab and Hyaluronidase for patients with multiple myeloma. This marks a significant milestone as it is the first approval for a new class of protein-degrading drugs aimed at treating this advanced blood cancer.
The approval of ZENBEXUS™ represents a notable advancement in the treatment landscape for multiple myeloma, providing new hope for patients facing this challenging disease. Bristol Myers Squibb's acquisition of the drug from Celgene underscores its commitment to expanding innovative treatment options in oncology.
Sources
Every quote below is verbatim from the article it is attributed to.
“U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluroni…”
SEC Filing — U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluroni…“<figure><div><img”
biopharma dive — Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene“The FDA approved a treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of drugs for the blood cancer.”
stat news — STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class